The efficacy of two different doses of hepatitis B immunoglobulin in interrupting mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis

Shan Fu
The first affiliated hospital of Xi'an JiaoTong University

Naijuan Yao
Peking University First Hospital of Xi'an JiaoTong University

YaLi Feng
The first affiliated hospital of Xi'an JiaoTong University

Juan Li
The first affiliated hospital of Xi'an JiaoTong University

YuChao Wu
The first affiliated hospital of Xi'an JiaoTong University

Zhen Tian
The first affiliated hospital of Xi'an JiaoTong University

Yuan Yang
The first affiliated hospital of Xi'an JiaoTong University

TaoTao Yan
The first affiliated hospital of Xi'an JiaoTong University

Yaolong Chen
Lanzhou University Evidence-Based Medicine center

Yingren Zhao
The first affiliated hospital of Xi'an JiaoTong University

Tianyan Chen
The first affiliated hospital of Xi'an JiaoTong University
| Jinfeng Liu | sourmilk2003@163.com |
|------------|----------------------|
| **Corresponding Author** | |

**DOI:** 10.21203/rs.2.19465/v1

**SUBJECT AREAS**  
*Infectious Diseases*

**KEYWORDS**  
*Hepatitis B, Immunoglobulins, mother-to-child transmission (MTCT)*
Abstract

**Background:** There isn’t consensus about the optimal dose of hepatitis B immunoglobulin (HBIG) in combination with hepatitis B vaccine to preventing mother-to-child transmission (MTCT) of hepatitis B virus (HBV).

**Methods:** We systematically searched MEDLINE, Embase, and Cochrane Library from database inception to Jan 16, 2019 for studies. The primary outcome was HBsAg and/or HBV DNA positive in infants at 6-12 months old. We performed a meta-analysis with a random-effects model to calculate a pooled estimate of MTCT.

**Results:** We included 31 studies, comprising of 12151 infants. There wasn’t significant differences in the pooled MTCT rates between 100 IU HBIG group and 200 IU HBIG group (5% vs 5%, \( P = 0.757 \)). When further stratified according to HBeAg status, in HBeAg(+) mothers, 7% (95%CI 4%-11%) infants became chronic HBV infection in 100 IU HBIG group compared to 7% (95%CI 5%-9%) in 200 IU group. The rates were 1% (95%CI 0%-2%) in 100IU group and 0% (95%CI 0%-1%) in 200IU group in infants born to HBeAg(-) mothers, respectively. When further comparing MTCT in infants from mothers with HBV DNA \( \geq 1 \times 10^6 \) IU/mL, the pooled MTCT rate was 12% (95%CI 7%-17%) in 100IU group and 8% (95%CI 5%-13%) in 200IU group, respectively. In addition, comparative analysis of four studies concerning two different dosages of HBIG further manifested the comparability.

**Conclusion:** 100 IU HBIG is sufficient in preventing MTCT for infants from chronic hepatitis B infected mothers, regardless of maternal HBeAg status or viral load.

**Background**

Hepatitis B virus (HBV) infection remains a major cause of chronic hepatitis and
associated morbidity and mortality worldwide\(^1\). Interrupting mother-to-child transmission (MTCT) has become the main priority for elimination HBV infection, especially in epidemic regions. Universal implementation of hepatitis B vaccine is the key strategy to preventing vertical (mother-to-child transmission) and horizontal transmission, and has manifested prominent effectiveness in reducing MTCT \(^2,3\).

As a passive immune agent against HBV, the first reported use of hepatitis B immunoglobulin (HBIG) to prevent MTCT was in 1978\(^4\). A few studies has demonstrated that immediate administration of HBIG play an essential role in the prevention of perinatal HBV infection\(^5\)\(^-\)\(^7\). Since then, active immunoprophylaxis with the hepatitis B vaccine in conjunction with HBIG were extensively administrated and the efficacy of has been fully confirmed \(^1\).

Nevertheless, there is no consensus on the recommended birth dosage of HBIG. At the very beginning, 0.5 ml HBIG per kg body-weight (1ml = 100 IU) displayed protection for MTCT\(^7\). A randomized blind controlled trial had further manifested the importance of HBIG (0.5 ml HBIG, 145 IU) in prevention of the perinatally transmission\(^8\). The recommended dosage of HBIG in different guidelines also varied among different countries. In the United States, the standard dose of HBIG was 0.5 mL for infants born to hepatitis B surface antigen positive (HBsAg(+)) women (HyperHEPATITIS B VACCINE S/D: 220 IU/mL, HepaGam: > 312 IU/mL, Nabi-HB: > 312 IU/mL)\(^9\). However, 100 IU HBIG was recommended to prevent MTCT in China\(^10\). Various dosages have been conducted in clinical practice. 100 IU, 200 IU, or even two doses of 200 IU HBIG were given to infants\(^11\)\(^-\)\(^13\). Whereas, considering efficacy and cost, the optimal dose of HBIG is still ambiguous. With the Decision Tree-Markov
model and cost-benefit analysis, Yang and his colleagues suggested that the optimal strategies was 200 IU HBIG at birth together with 3 schedules of vaccination\textsuperscript{14}. A prospective cohort study conducted by Wei et al. highlighted that one birth dose of 100 IU HBIG was comparable to 200 IU\textsuperscript{15}. Up to present, few studies has compared the efficacy of different dosages of HBIG combined with hepatitis B vaccine in preventing MTCT of hepatitis B virus, and systematic review is absent. Therefore, we performed a systematic review and meta-analysis to assess the effectiveness of 100 IU and 200 IU HBIG, which will provide evidence for developing strategies for MTCT prevention.

Methods

Search strategy

This systematic review and meta-analysis was performed using a preplanned protocol (registered in PROSPERO: CRD42019130398). Systematic reviews about the efficacy of different dosages of HBIG in infants had not been found. Firstly, we searched the studies reporting on MTCT after passive-active immunoprophylaxis in HBV mothers, conforming to the Preferred Reporting Items for Systematic reviews and Meta Analysis (PRISMA) guidelines\textsuperscript{16}. Two reviewers (SF and NJY) searched PubMed, Embase, and Cochrane Library, for studies published in English or Chinese from inception to Jan 16, 2019. Search strategy included terms related to HBV ( eg, “HBV” or “hepatitis B” or “hepatitis B virus”), infant ( eg, “neonate” or “newborn” or “infant”) and Immunization ( eg, “Hepatitis B Vaccines” or “Vaccination” or “vaccin*” or “Hepatitis B immunoglobulin” or “Immunization” or “Immunoprophylaxis”). Additionally, we also manually screened the reference lists
of primary studies and review articles for additional references.

**Inclusion and exclusion criteria**

Two independent reviewers (SF and NJY) screened the titles and abstracts for eligibility using pre-specified inclusion/exclusion criteria. No type of study restriction was imposed. Our rationale was that inclusion of publications reporting on children, from chronic hepatitis B infected (CHB) women without intervention during pregnancy, were administrated full-course implementation of hepatitis B vaccine and one birth dose of 100IU or 200IU HBIG. The studies were included if they presented the rate of immonoprophylaxis failure, which was defined as HBsAg and/or HBV DNA positive in infants at 6-12months old. We excluded studies in which pregnant women were co-infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis D virus (HDV), syphilis, toxoplasmosis, herpes virus, rubella virus, or cytomegalovirus; infants were preterm, congenital abnormality or developmental disorders; sample size<10; or studies published as abstracts only. If there were more than one report from the same research center, we selected the most recent report or the report with the most complete data including subgroup data.

**Data abstraction and quality assessment**

Two reviewers independently extracted data according to inclusion/exclusion criteria. We developed a case report form (CRF) to extract the following information from each study: first authors’ name, year of publication, study design, countries/regions, maternal hepatitis B e-antigen (HBeAg) status, maternal HBV DNA level before delivery, intervention for infants, dosage of HBIG, time of HBIG administered, time point of immunogenicity assessment, sample size, and relevant outcome data. Disagreements were resolved by consensus with the other authors.
We contacted authors to obtain clarification for studies with unclear methods or insufficient date. The quality of the randomized controlled trials (RCTs) was evaluated using the Cochrane Risk of Bias assessment tool, and studies were classified as low risk of bias, unclear/medium risk of bias or high risk of bias. With Newcastle-Ottawa scale (NOS), observational studies with a cumulative score ≥ 7, 4-6, and < 4 were considered as high, fair, and low quality, respectively.

Statistical analysis

We performed proportion meta-analyses to estimate the rate of immunoprophylaxis failure of two different doses of HBIG, and head-to-head meta-analyses to directly compare the efficacy of 100IU and 200IU HBIG. Statistical analysis was carried out according to the per-protocol analysis data, and relative risk (RR) and 95% confidence interval (95%CI) were estimated by the Mantel-Haenszel fixed-effects model, or the inverse variance random effects model. The heterogeneity test was assessed using the $\chi^2$-squared test and $I^2$ statistics, with $I^2$ statistics 25%-50%, 50%-75%, and > 75% indicated a low, moderate, and high degree of heterogeneity, respectively. Subgroups analyses were performed for potential sources of heterogeneity. Stata (version 13.1; Stata, College Station, TX, USA) was used for proportion meta-analyses, and RevMan 5.3 (Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark) for head-to-head meta-analyses. $P$ value < 0.05 was considered statistically significant.

Results

Characteristics of the eligible studies

Of the 5789 citations and 6 additional manually searched articles evaluated, 359
studies were eligible for full-text review, thirty-one of which were included in our analysis. All studies except four were published in English. Included studies were conducted in five countries, China, Turkish, Greece, Australian, and Japan, from 1999 to 2018. Data on study characteristics were shown in Table 1. All enrolled infants were administered with HBIG within 24 h after birth. The levels of HBsAg and/or HBV DNA were detected at 6–12 months old. The methodological quality of the included studies are reported in the appendix Table S1 and Table S2.

| First author, year | Country | Study design | Study period | Immunization strategy | Age for assessment | Dosage of HBIG | n  |
|--------------------|---------|--------------|--------------|-----------------------|-------------------|----------------|----|
| Wei 2018^15        | China   | cohort study | 2009–2011    | HBIG within 12 h + HepB within 12 h, 1, 6 m | 7 m               | 100            | 545 |
| Sheng 2018^11      | China   | cross-sectional study | 1/2016–12/2016 | HBIG within 12 h + HepB within 12 h, 1, 6 m | 7 m               | 100            | 46  |
| He 2018^17         | China   | cohort study | 12/2008–5/2016 | HBIG within 6 h + HepB within 12 h, 1, 6 m | 7 m               | 200            | 34  |
| Chen 2018^18       | China   | cross-sectional study | 12/2010–12/2015 | HBIG within 12 h + HepB within 12 h, 1, 6 m | 7 m               | 200            | 499 |
| Zhu 2017^19        | China   | RCT          | NA           | HBIG within 24 h + HepB within 12 h, 1, 6 m | 7 m               | 200            | 12  |
| Pan 2017^21        | China   | cohort study | 5/2008–1/2015 | HBIG within 6 h + HepB within 12 h, 1, 6 m | 7 m               | 200            | 89  |
| Kang               | China   | cross-       | 1/2011       | HBIG                  | 7-12m             | 100            | 114 |
|                    |         | section study|              |                       |                   | 2765           |     |
| Year  | Country | Study Design | Dates            | Methodology | Duration | Follow-up | Events | 
|-------|---------|--------------|------------------|-------------|----------|-----------|--------| 
| 2017  | China   | Sectional study | 7/2011-7/2011     | within 24 h + HepB within 24 h, 1.6 m | 7 m      | 200       | 23     | 
| 2017  | China   | Cohort study  | 1/2011-6/2015     | HBIG within 6 h + HepB within 6 h, 1.6 m | 7 m      | 200       | 23     | 
| 2017  | China   | Cross-sectional study | 8/2012-12/2013   | HBIG within 24 h + HepB within 24 h, 1.6 m | 7 m      | 200       | 23     | 
| 2016  | China   | Cohort study  | 12/2010-12/2012   | HBIG + HepB within 24 h, 1.6 m | 51w      | 100       | 19     | 
| 2016  | China   | RCT          | NA               | HBIG within 24 h + HepB within 24 h, 1.6 m | 7 m      | 200       | 23     | 
| 2016  | China   | Case-control study | 1/2008-3/2011    | HBIG within 6 h + HepB within 6 h, 1.6 m | 7 m      | 200       | 23     | 
| 2016  | China   | Cohort study  | 7/2012-4/2015     | HBIG within 2 h + HepB within 2 h, 1.6 m | 7 m      | 100       | 16     | 
| 2016  | China   | Cohort study  | 1/2012-3/2015     | HBIG within 6 h + HepB within 6 h, 1.6 m | 7 m      | 200       | 23     | 
| 2016  | China   | RCT          | 3/2012-6/2013     | HBIG within 12 h + HepB within 12 h, 1.6 m | 7 m      | 200       | 23     | 
| 2015  | China   | Cohort study  | 2009-2013         | HBIG 30 min,15 d + HepB30min, 1.6m* | 7 m      | 100       | 0      | 
| 2015  | Turkey  | Cohort study  | 5/2013-9/2013     | HBIG within 24 h + HepB within 24 h, 1.6 m | 24-36w    | 200       | 2      | 
| 2015  | China   | CCT          | 1/2011-1/2014     | HBIG + HepB0.1,6 m | 6 m      | 200       | 4      | 
| 2015  | China   | RCT          | 2011-2013         | HBIG within 24 h + HepB within 24 h, 1.6 m | 6 m      | 100       | 6      | 
| 2014  | China   | Case-control study | 1/2011-6/2011    | HBIG + HepB0.1,6 m | 7-10m     | 100       | 9      | 

* Duration in weeks for HBIG administration.
| Study | Country | Design | Dates | HBIG & HepB Schedule | Event | Number of Infected Infants | Number of Total Infants |
|-------|---------|--------|-------|-----------------------|-------|---------------------------|------------------------|
| Kang 2014 | China | Single-arm study | 1/2011-6/2011 | HBIG at birth + HepB 0.1.6 m | 7-10m | 100 | 54 | 1907 |
| Yin 2013 | China | unclear | 6/2006-3/2010 | HBIG within 6 h + HepB within 6 h, 1.6 m | 7 m | 200 | 9 | 820 |
| Sun 2012 | China | RCT | 2009-2011 | HBIG within 12 h + HepB0, 1.6 m | 7 m | 100 | 4 | 240 |
| Koumbi 2010 | Greece | unclear | NA | HBIG within 24 h + HepB within 24 h, 1.6 m | 7 m | 200 | 0 | 23 |
| Xu 2009 | China | RCT | NA | HBIG within 24h + HepB within 24 h, 4,24 w | 52w | 200 | 5 | 41 |
| Wiseman 2009 | Australia | prospective observational study, single-arm | 8/2002-5/2008 | HBIG within 12h + HepB within 12 h, 2, 4, 6 m | 9 m | 100 | 4 | 138 |
| Deng 2008 | China | RCT | 9-2006.12 | HBIG within 12 h, 1 m + HepB0, 1.6m* | 8 m | 100 | 14 | 85 |
| Xiao 2007 | China | cohort study | 9/2001-6/2005 | HBIG within 12h + HepB 1d, 1.6 m | 6 m | 100 | 12 | 152 |
| Yuan 2006 | China | RCT | 11/1999-3/2004 | HBIG at birth + HepB within 24 h, 1.6 m | 12 m | 200 | 17 | 133 |
| Wang 2002 | China | cohort study | 1990-1998 | HBIG at birth + HepB 1.2, 7 m | 7 m | 100 | 21 | 292 |
| Kato 1999 | Japan | single-arm study | 1981-1993 | HBIG at birth + HepB within 2 m, 3-5, 6m | 12 m | 200 | 17 | 203 |

RCT, randomized controlled trial; CCT, control clinical trial; NA, not applicable; h, hour; w, week; m, month

Among the thirty-one studies included, nine studies evaluated by the Cochrane Risk of Bias assessment tool, consisted of six with low risk of bias and three with...
unclear/medium risk of bias, the thirteen observational studies evaluated by NOS score, consisted of eleven with high quality and two with medium quality, while the remaining nine studies could not be evaluated due to unclear design.

Overall efficacy of different doses HBIG in MTCT

Among thirty-one studies included, twenty-nine studies comprised of 11891 infants were eligible for proportion meta-analyses, and the other two\textsuperscript{31,40} including 260 infants were only applied for head-to-head meta-analysis because the infants were administrated with two doses of HBIG.

In the proportion meta-analyses, two studies contributed both 100 IU and 200 IU datasets. 7266 infants receiving 100 IU HBIG from twelve studies, and 4625 infants receiving 200 IU HBIG from nineteen studies were included. For 100 IU group, the pooled MTCT rate was 5% (95%CI 3%-7%), and a similar rate was observed in 200 IU group (5%, 95%CI 3%-7%) (Fig. 2a). Of the four studies eligible for head-to-head meta-analyses, 894 infants received 100 IU and 1030 infants received 200 IU HBIG.

In addition, there wasn't significant difference in the risk of MTCT between these two groups (RR = 1.08, 95%CI 0.64–1.82, P = 0.77) (Fig. 2b).

Subgroups analysis by Hepatitis B e antigen (HBeAg) status

A plenty of studies have confirmed that HBeAg is an independent risk factor for MTCT\textsuperscript{22}. Data were further stratified to evaluate the effectiveness of the two different doses by maternal HBeAg status. As shown in Fig. 3a, 2319 infants from eighteen studies were born to HBeAg (+) mothers. The pooled MTCT rate was 7% (95%CI 4%-11%) for infants receiving 100 IU HBIG (n = 707), there wasn’t obvious difference between 100 IU vs 200 IU group (7%, 95%CI 5%-9%, P = 0.871). Further head-to-head meta-analysis using data from two studies (n = 591) confirmed this
result (RR = 0.84, 95%CI 0.39–1.77, P = 0.64) (Fig. 3b). For infants born to HBeAg (-) mothers, the estimated incidence of immonoprophylaxis failure was 1% (95%CI 0–2%) in 100 IU group (n = 1415) and 0% (95%CI 0–1%) in 200 IU group (n = 2157), respectively (Fig. 4).

Subgroups analysis by maternal HBV DNA level

As we all known, HBV DNA load is closely correlated with MTCT, especially in CHB pregnant women with high viremia⁴⁵. Efficacy of different doses HBIG based on HBV DNA level before delivery was carried out. 12 datasets including 1652 infants provided data of maternal HBV DNA ≥ 1 × 10^6 IU/mL before delivery. As showed in Fig. 5, the pooled MTCT rate was 12% (95%CI 7%-17%) across 686 infants administered 100 IU HBIG and 8% (95%CI 5%-13%) across 966 infants administered 200 IU HBIG, respectively. However, no significant difference was found in these two groups (P = 0.265). Regarding head-to-head meta-analyses for high HBV virus load, there was insufficient sample size to analyze.

Discussion

To our knowledge, this is the first comprehensive analysis to compare the effectiveness of two different doses of HBIG in preventing MTCT, in which strict inclusion or exclusion criteria was implemented and the definition of hepatitis B virus MTCT was clear and unified for all included studies (defined as HBsAg and/or HBV DNA positive in infants at 6-12months old). Our systematic review emphasized the similar efficacy of different doses of HBIG in preventing hepatitis B virus MTCT, regardless of maternal HBeAg status or HBV DNA virus load before delivery. HBIG is a purified product of human immunoglobulin from human plasma including high titers of hepatitis B surface antibody and prevent and decrease HBV
infection. It is noteworthy that a critical step has been made in preventing hepatitis B virus with combined implementation of HBIG and hepatitis B vaccine in infants.

Previous studies including ours has shown about 29% (95%CI 13%-49%) infants obtained HBV infection from CHB mothers without intervention. In current study, HBIG with hepatitis B vaccine had decreased the rate of MTCT in a great degree, with a pooled rate of 5%. Furthermore, the 100 IU and 200 IU HBIG had shown identical effectiveness in MTCT. The results were consistent with a recent study by Wei et al, which showed that the performance of 100 IU is comparable with 200 IU HBIG in interrupting MTCT of HBV, with the rate of 4.3% in 100 IU and 5.2% in 200 IU (P = 0.669).

When further subgroup analysis according maternal HBeAg status, a pooled rate of 7% was shown in infants from HBeAg (+) mothers, and no difference was displayed with different doses. Whereas, a pooled MTCT as low as zero (95%CI 0-1%) was shown in 200 IU HBIG group and 1% (95%CI 0-2%) in 100 IU HBIG group among infants from HBeAg (-) mothers. A few studies have showed that Hepatitis B vaccine alone may be sufficient for preventing hepatitis B virus transmission in neonates of HBeAg(-) mothers. However, there still were infected cases reported in HBeAg (-) mothers with vaccine only. Considering the high risk of exposure to HBV during delivery and immature immune function of neonates, MTCT may still occur. Moreover, it is easier for neonates to become chronic carriers once infected with HBV. It should be very cautious to recommend hepatitis B vaccine only to this population.

Maternal high viremia is an independent risk factor for MTCT. In this meta-
analysis, 200 IU HBIG showed a higher protective rate than 100 IU HBIG (12% vs. 8%) in infants from CHB mothers with HBV DNA ≥ 10^6 IU/mL before delivery, whereas, there was no statistical difference between these two groups (P = 0.265). Wang CM and her colleagues had also shown the similar efficacy of different doses of HBIG in protecting infants from HBV infection, despite 200 IU HBIG exhibited superior to 100 IU in production of HBsAb, which attributed to high dosage of vaccine. In view of above results, 100 IU HBIG may be sufficient, even for infants from high viremia mothers. However, due to lack of head-to-head meta-analysis, further studies are necessary to evaluate efficacy and cost-effectiveness for 200 IU in infants from mothers with HBV DNA ≥ 10^6 IU/mL.

This mete-analysis had several limitations. Firstly, there were not insufficient studies for directly comparing the efficacy. Secondly, there were only two studies eligible for head-to-head meta-analysis to evaluate the efficacy in HBeAg (+) mothers. Moreover, limited data were available regarding high HBV DNA, which precluded us from head-to-head meta-analysis. In addition, due to the limitation of primary studies, there were insufficient data to estimate the efficacy in preterm or low birth weight infants, which is a matter of great concern. Finally, as all literature included were published in English or Chinese and the vast majority of data were drawn from studies in China, further researches are essential to generalize the results worldwide.

Conclusion

In conclusion, our meta-analysis highlighted that similar effectiveness was estimated in 100 IU and 200 IU HBIG combined with hepatitis B vaccine in preventing MTCT, regardless of maternal HBeAg status or HBV DNA virus load before
delivery. Owing to the excessively demanding storage condition and unaffordable price in developing countries, with a predominating portion of HBV infected population, 100 IU HBIG combined with hepatitis B vaccine is reasonable to be recommended in preventing MTCT.

Abbreviations

HBV: Hepatitis B virus; HBIG: hepatitis B immunoglobulin; MTCT: mother-to-child transmission; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e-antigen; CHB: chronic hepatitis B infected; RR: relative risk; CI: confidence interval

Declarations

Acknowledgements

We would like to thank Nan Yang and XunFei Luo, from the Department of Evidence-Based Medicine Center, Basic Medical Sciences, Lanzhou University, provided the guidance on methodologies.

Authors’ contributions

Guarantor of the article: JF L, TY C

Study design: SF, NJ Y, YL C, YR Z, JF L, TY C

Data collection, data analysis, data interpretation: SF, NJ Y, YC W, Z T

Quality assessment: YY, TT Y, YL F, JL

Drafting of the manuscript: SF, NJ Y, JF L

All authors have approved the final draft of the manuscript.

SF and NJ Y contributed equally to this work and share first authorship

Funding

None.
Availability of data and materials

All relevant data for this study have been added as additional files.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

All the authors declare that they have no financial and non-financial competing interests.

References

1. Polaris Observatory C. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403.

2. Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents. The lancet Gastroenterology hepatology. 2019;4(6):466–76.

3. Campos-Outcalt D. Practice Alert: ACIP vaccine update. J Fam Pract. 2018;67(3):155–8.

4. Beasley RP, Stevens CE. Vertical transmission of HBV and interruption with globulin. Viral hepatitis 1978: 333–45.

5. Beasley RP, Hwang LY, Lin CC, et al. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial. Lancet. 1981;2(8243):388–93.

6. Beasley RP, Hwang LY, Stevens CE, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology. 1983;3(2):135–41.

7. Reesink HW, Reerink-Brongers EE, Lafeber-Schut BJ, Kalshoven-Benschop J, Brummelhuis HG. Prevention of chronic HBsAg carrier state in infants of HBsAg-positive mothers by hepatitis B immunoglobulin. Lancet. 1979;2(8140):436–8.

8. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2(8359):1099-
Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recommendations reports: Morbidity mortality weekly report Recommendations reports. 2005;54(Rr-16):1–31.

Hepatology CSO, Association CM. Consensus on the management of hepatitis B virus infection in women of childbearing age. J Clin Hepatol. 2018; Vol.34 No.6, Jun.2018.

Sheng QJ, Wang SJ, Wu YY, Dou XG, Ding Y. Hepatitis B virus serosurvey and awareness of mother-to-child transmission among pregnant women in Shenyang, China: An observational study. Medicine. 2018;97(22):e10931.

Pan CQ, Duan Z, Dai E, et al. Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. New England journal of medicine. 2016;374(24):2324–34.

Sun W, Zhao S, Ma L, et al. Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission. BMC Gastroenterol. 2017;17(1):51.

Yang N, Meng Y, Zhou N, Lei L, Hu M. Cost-Benefit analysis of Hepatitis B Vaccination Strategies for Preventing Mother-to-Child Transmission: A Decision Tree-Markov Model. Value in Health 2018; 21.

Wei KP, Zhu FC, Liu JX, et al. The efficacy of two different dosages of hepatitis B immunoglobulin combined with hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus: A prospective cohort study. Vaccine. 2018;36(2):256–63.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9, W64.

He T, Bai Y, Cai H, et al. Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B. Hepatology international. 2018;12(2):118–25.

Chen T, Wang J, Qiu H, et al. Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China. Medicine. 2018;97(27):e11406.

Zhu F, Deckx H, Roten R, Michiels B, Sarnecki M. Comparative Efficacy, Safety and Immunogenicity of Hepavax-Gene TF and Engerix-B Recombinant Hepatitis B Vaccines in Neonates in China. Pediatr Infect Dis J. 2017;36(1):94–101.

Zhou S, Li T, Allain JP, et al. Low occurrence of HBsAg but high frequency of transient occult HBV infection in vaccinated and HBIG-administered infants born to HBsAg positive mothers. Journal of medical virology. 2017;89(12):2130–7.
21. Pan CQ, Yi W, Liu M, Wan G, Hu YH, Zhou MF. Lamivudine therapy during the second vs the third trimester for preventing transmission of chronic hepatitis B. Journal of viral hepatitis. 2017;24(3):246–52.

22. Kang W, Li Q, Shen L, et al. Risk factors related to the failure of prevention of hepatitis B virus Mother-to-Child transmission in Yunnan, China. Vaccine. 2017;35(4):605–9.

23. Chen ZX, Gu GF, Bian ZL, et al. Clinical course and perinatal transmission of chronic hepatitis B during pregnancy: A real-world prospective cohort study. J Infect. 2017;75(2):146–54.

24. Zhu FC, Sun KX, Pan HX, et al. The immunogenicity in healthy infants and efficiency to prevent mother to child transmission of Hepatitis B virus of a 10 µg recombinant yeast-derived Hepatitis B vaccine (Hep-KSC). Vaccine. 2016;34(24):2656–62.

25. Yin Y, Zhang P, Tan Z, Zhou J, Wu L, Hou H. The association of Pre-S/S gene mutations and hepatitis B virus vertical transmission. Hepatitis Monthly 2016; 16(3).

26. Wang C, Wang C, Jia ZF, et al. Protective effect of an improved immunization practice of mother-to-infant transmission of hepatitis B virus and risk factors associated with immunoprophylaxis failure. Medicine. 2016;95(34):e4390.

27. Tan Z, Yin Y, Zhou J, Wu L, Xu C, Hou H. Telbivudine treatment of hepatitis B virus-infected pregnant women at different gestational stages for the prevention of mother-to-child transmission: Outcomes of telbivudine treatment during pregnancy. Medicine. 2016;95(40):e4847.

28. Liu Y, Wang M, Yao S, et al. Efficacy and safety of telbivudine in different trimesters of pregnancy with high viremia for interrupting perinatal transmission of hepatitis B virus. Hepatology research. 2016;46(3):E181-E8.

29. Tekin Koruk S, Batirel A, Kose S, et al. Evaluation of hepatitis B virus transmission and antiviral therapy among hepatitis B surface antigen-positive pregnant women. J Obstet Gynaecol Res. 2015;41(12):1870–6.

30. Deng Y, Wu W, Zhang D, et al. [The safety of telbivudine in preventing mother-to-infant transmission of hepatitis B virus in pregnant women after discontinuation]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 2015;23(8):586–9.

31. Cuimin W, Guorong H, Hongxiu J, Naiying K, Yan W, Jinmei S. Comparison of combined immunization schemes influence on anti-HBs of babies born to mothers with highload hepatitis B virus infection. Chinese Journal of Hepatology. 2015;23(7):493–7.

32. Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015;62(2):375–86.

33. Zhang Z, Li A, Xiao X. Risk factors for intrauterine infection with hepatitis B virus. Int J Gynaecol
34. Kang W, Ding Z, Shen L, et al. Risk factors associated with immunoprophylaxis failure against mother to child transmission of hepatitis B virus and hepatitis B vaccination status in Yunnan province. China Vaccine. 2014;32(27):3362-6.

35. Yin Y, Wu L, Zhang J, Zhou J, Zhang P, Hou H. Identification of risk factors associated with immunoprophylaxis failure to prevent the vertical transmission of hepatitis B virus. J Infect. 2013;66(5):447-52.

36. Xiang S, Feng-cai ZX-jZ. Wei-guo, X, et al. Comparing the efficacy of passive-active immunoprophylaxis using different doses of hepatitis B immunoglobulin in newborns of HBsAg positive mothers. ACTA UNIVERSITATIS MEDICINALIS NANJING(Natural Science). 2012;32(04):491–4.

37. Koumbi L, Bertoletti A, Anastasiadou V, et al. Hepatitis B-specific T helper cell responses in uninfected infants born to HBsAg+/HBeAg- mothers. Cell Mol Immunol. 2010;7(6):454–8.

38. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. Journal of viral hepatitis. 2009;16(2):94–103.

39. Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: an Australian experience. The Medical journal of Australia. 2009;190(9):489–92.

40. Deng Yu, Li Juan, Li WeiQun, Qian Z. Comparison of the effects of different doses of hepatitis B immunoglobulin in blocking mother-to-child transmission of hepatitis B virus. JOURNAL OF COMMUNITY MEDICINE. 2008;6(13):30-1.

41. Xiao XM, Li AZ, Chen X, Zhu YK, Miao J. Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy. Int J Gynaecol Obstet. 2007;96(3):167–70.

42. Yuan J, Lin J, Xu A, et al. Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single-centre randomized study. Journal of viral hepatitis. 2006;13(9):597–604.

43. Wang J, Zhu Q, Zhang X. Effect of delivery mode on maternal-infant transmission of hepatitis B virus by immunoprophylaxis. Chin Med J. 2002;115(10):1510–2.

44. Kato H, Nakata K, Hamasaki K, et al. Long-term efficacy of immunization against hepatitis B virus in infants at high-risk analyzed by polymerase chain reaction. Vaccine. 1999;18(7-8):581–7.

45. Liu JF, Yao NJ, Chen TY, et al. Prevalence of mother-to-child transmission of hepatitis B virus: A systematic review and meta-analysis. Journal of hepatology. 2019;70:E123-E4. http://dx.doi.org/10.1016/S0168-8278(19)30217-8.

46.

http://dx.doi.org/10.1016/S0168-8278(19)30217-8.
Li XM, Yang YB. HY H. Interruption of HBV intrauterine transmission: a clinical study. World Journal of Gastroenterology 2003 World Journal of Gastroenterology. 2003;9(7):1501–3.

47.

Lu Y, Liang XF, Wang FZ, et al. Hepatitis B vaccine alone may be enough for preventing hepatitis B virus transmission in neonates of HBsAg (+)/HBeAg (-) mothers. Vaccine. 2017;35(1):40–5.

48.

Machaira M, Papaevangelou V, Vouloumanou EK, Tansarli GS, Falagas ME. Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis. J Antimicrob Chemother. 2015;70(2):396–404.

49.

Adkins B. T-cell function in newborn mice and humans. Immunology today. 1999;20(7):330–5.

50.

Guo Z, Shi XH, Feng YL, et al. Risk factors of HBV intrauterine transmission among HBsAg-positive pregnant women. Journal of viral hepatitis. 2013;20(5):317–21.

51.

Li XM, Shi MF, Yang YB, et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World journal of gastroenterology. 2004;10(21):3215–7.

Figures
Figure 1

Flow chart of the study screening and selection for inclusion in the meta-analysis
Figure 1

Flow chart of the study screening and selection for inclusion in the meta-analysis
Figure 2

Overall efficacy of 100IU or 200IU HBIG in MTCT. A. Pooled estimates of MTCT rate.
Overall efficacy of 100IU or 200IU HBIG in MTCT. A. Pooled estimates of MTCT rates; B. The rate of immunoprophylaxis failure in infants born to CHB mothers (head-to-head meta-analyses).
Figure 3

Subgroups analysis by Hepatitis B e antigen (HBeAg) status in MTCT A. Pooled est
Figure 3

Subgroups analysis by Hepatitis B e antigen (HBeAg) status in MTCT. A. Pooled estimates of MTCT rates in infants born to HBsAg+/HBeAg+ mothers (proportion meta-analyses).
Figure 4

Pooled estimates of MTCT rates in infants born to HBsAg+/HBeAg- mothers
Figure 5

Pooled estimates of MTCT rates in infants born to high viremia mothers (HBV DNA
Figure 5

Pooled estimates of MTCT rates in infants born to high viremia mothers (HBV DNA

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to
download.

Additional file 2.docx
Additional file 1.docx
Additional file 2.docx
Additional file 1.docx